PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
16685210-7	2006	In DS/H rats, treatment with candesartan did not alter blood pressure, but resulted in a marked improvement of the hemodynamic deterioration; these therapeutic effects were accompanied by decreases in myocardial NADPH oxidase activity, TBARS contents and the expression of TGF-beta, CTGF, p22phox, gp91phox and UCP-2.	candesartan	29-40	cytochrome b-245 alpha chain	Rattus norvegicus	289-296	
18853323-4	2008	We also evaluated the effect of an ARB (2.5 mg/kg/day candesartan) or angiotensin II (500 ng/kg/min) on retinal gene expressions of VEGF and p22phox, a subunit of NADPH oxidase.	candesartan	54-65	cytochrome b-245 alpha chain	Rattus norvegicus	141-148	
18853323-8	2008	At 50 weeks, significant increases in VEGF and p22phox, an NADPH oxidase subunit, were significantly reduced by candesartan.	candesartan	112-123	cytochrome b-245 alpha chain	Rattus norvegicus	47-54	
23764378-10	2013	Aortic eNOS and nNOS  fell and p22phox and Mn SOD increased in hypertensive I3C-induced TGRs; all changes were reversed with candesartan.	candesartan	125-136	cytochrome b-245 alpha chain	Rattus norvegicus	31-38	
22421905-7	2012	Candesartan alone, but not amlodipine alone, significantly attenuated vascular superoxide and NADPH oxidase subunit p22phox in SHRcp.	candesartan	0-11	cytochrome b-245 alpha chain	Rattus norvegicus	116-123	
22421905-8	2012	Amlodipine added to candesartan synergistically enhanced the reduction of vascular p22phox levels and superoxide by candesartan in SHRcp, suggesting the association of vascular insulin resistance with oxidative stress.	candesartan	20-31	cytochrome b-245 alpha chain	Rattus norvegicus	83-90